Injunctive Relief: The tide is turning

Whether it is Neurim Pharmaceuticals v Mylan in UK court or Mylan v Cipla in Federal court of Australia, Pharmaceutical companies seeking to launch or prevent the launch of generic or biosimilar products cannot afford to ignore the fundamental shift in the Court’s position. Would Indian Courts follow the suit…….. hear from experts.

13 views0 comments